Compare FCX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCX | SNY |
|---|---|---|
| Founded | 1987 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.9B | 104.5B |
| IPO Year | 1994 | 2001 |
| Metric | FCX | SNY |
|---|---|---|
| Price | $69.11 | $40.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 10 |
| Target Price | ★ $72.45 | $53.72 |
| AVG Volume (30 Days) | ★ 7.9M | 2.1M |
| Earning Date | 10-22-2026 | 10-30-2026 |
| Dividend Yield | 0.86% | ★ 4.28% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $25,915,000,000.00 | N/A |
| Revenue This Year | $14.52 | $2.00 |
| Revenue Next Year | $19.17 | $6.29 |
| P/E Ratio | $55.38 | ★ $6.14 |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $38.54 | $40.40 |
| 52 Week High | $80.24 | $52.68 |
| Indicator | FCX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 41.50 |
| Support Level | $66.29 | $41.19 |
| Resistance Level | $70.66 | $45.22 |
| Average True Range (ATR) | 1.93 | 0.46 |
| MACD | -0.49 | -0.09 |
| Stochastic Oscillator | 19.77 | 38.62 |
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.1 million metric tons of copper (its share) in 2025, making it the one of the world's largest copper miners by volume. It also sold about 530,000 ounces of gold, mostly from Grasberg, and 74 million pounds of molybdenum. It had about 25 years of copper reserves at the end of December 2025. We expect it to sell about 1.3 million metric tons of copper and 610,000 ounces of gold midcycle in 2030.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.